Here are the 10-K annual reports from Nektar Therapeutics (NKTR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NKTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKTR filings page.
Nektar Therapeutics is a clinical-stage biopharma focused on immunotherapy for autoimmune disease and cancer. Its lead asset, rezpegaldesleukin, targets IL‑2 receptors to expand regulatory T cells and is in Phase 2b trials for atopic dermatitis and alopecia areata, with FDA Fast Track designations for both indications.
In the REZOLVE‑AD study, rezpegaldesleukin achieved statistically significant improvements in standard eczema scores and itch at 16 weeks and showed durable responses out to 52 weeks with favorable tolerability, mainly mild injection site reactions. REZOLVE‑AA topline data showed meaningful hair regrowth trends and supportive safety, with statistical significance when four ineligible patients were excluded.
The pipeline also includes preclinical TNFR2 agonist antibodies NKTR‑0165 and NKTR‑0166 for autoimmune disease, oncology candidate NKTR‑255 targeting IL‑15 in combination studies, and preclinical PEG‑CSF1 program NKTR‑422. Nektar reported research and development expense of $117,330 (in thousands) for 2025 and remains dependent on future partnerships and sufficient capital to advance its programs.